JP2009523781A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009523781A5 JP2009523781A5 JP2008550880A JP2008550880A JP2009523781A5 JP 2009523781 A5 JP2009523781 A5 JP 2009523781A5 JP 2008550880 A JP2008550880 A JP 2008550880A JP 2008550880 A JP2008550880 A JP 2008550880A JP 2009523781 A5 JP2009523781 A5 JP 2009523781A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- derivative
- group
- substituted
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 9
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- -1 (4-methoxyphenoxy) -phenyl Chemical group 0.000 claims 7
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 7
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 6
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 235000010290 biphenyl Nutrition 0.000 claims 4
- 239000004305 biphenyl Substances 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- NIONDZDPPYHYKY-SNAWJCMRSA-N (2E)-hexenoic acid Chemical compound CCC\C=C\C(O)=O NIONDZDPPYHYKY-SNAWJCMRSA-N 0.000 claims 3
- VFZQATFTQAZCMO-UHFFFAOYSA-N 6-chlorochromen-4-one Chemical compound O1C=CC(=O)C2=CC(Cl)=CC=C21 VFZQATFTQAZCMO-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000004001 thioalkyl group Chemical group 0.000 claims 3
- 229930192474 thiophene Natural products 0.000 claims 3
- 150000000093 1,3-dioxanes Chemical class 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 102000000536 PPAR gamma Human genes 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 208000001280 Prediabetic State Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 150000004862 dioxolanes Chemical class 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 1
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 claims 1
- TUJMFENFEJTHDG-UHFFFAOYSA-N 2,4-diphenyl-1,3-dioxane Chemical class O1CCC(C=2C=CC=CC=2)OC1C1=CC=CC=C1 TUJMFENFEJTHDG-UHFFFAOYSA-N 0.000 claims 1
- NIONDZDPPYHYKY-UHFFFAOYSA-N 2-hexenoic acid Chemical compound CCCC=CC(O)=O NIONDZDPPYHYKY-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010036030 Polyarthritis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000005236 alkanoylamino group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 150000008371 chromenes Chemical class 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000532 dioxanyl group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000004971 nitroalkyl group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000030428 polyarticular arthritis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76024106P | 2006-01-18 | 2006-01-18 | |
| PCT/IB2007/002542 WO2007138485A2 (en) | 2006-01-18 | 2007-01-18 | Ppar modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012286467A Division JP2013060465A (ja) | 2006-01-18 | 2012-12-28 | Ｐｐａｒ調節因子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009523781A JP2009523781A (ja) | 2009-06-25 |
| JP2009523781A5 true JP2009523781A5 (enExample) | 2010-02-12 |
Family
ID=38779054
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008550880A Pending JP2009523781A (ja) | 2006-01-18 | 2007-01-18 | Ｐｐａｒ調節因子 |
| JP2012286467A Withdrawn JP2013060465A (ja) | 2006-01-18 | 2012-12-28 | Ｐｐａｒ調節因子 |
| JP2015141004A Ceased JP2015180703A (ja) | 2006-01-18 | 2015-07-15 | Ｐｐａｒ調節因子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012286467A Withdrawn JP2013060465A (ja) | 2006-01-18 | 2012-12-28 | Ｐｐａｒ調節因子 |
| JP2015141004A Ceased JP2015180703A (ja) | 2006-01-18 | 2015-07-15 | Ｐｐａｒ調節因子 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20110178112A1 (enExample) |
| EP (2) | EP2363127A1 (enExample) |
| JP (3) | JP2009523781A (enExample) |
| CN (3) | CN101657100A (enExample) |
| AU (1) | AU2007266714B2 (enExample) |
| CA (1) | CA2637803A1 (enExample) |
| DK (1) | DK1976509T3 (enExample) |
| ES (1) | ES2533652T3 (enExample) |
| IN (1) | IN2015DN00502A (enExample) |
| MX (1) | MX2008009241A (enExample) |
| PL (1) | PL1976509T3 (enExample) |
| RU (1) | RU2449999C2 (enExample) |
| WO (1) | WO2007138485A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008206048A1 (en) | 2007-01-18 | 2008-07-24 | Evolva Sa | Substituted 1,3-dioxanes and their uses |
| JP2010516700A (ja) | 2007-01-18 | 2010-05-20 | エヴォルヴァ エスアー | 置換１，３−ジオキサンおよびそれらの使用 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2011057262A2 (en) * | 2009-11-09 | 2011-05-12 | Evolva Inc. | Treatment of infections with tp receptor antagonists |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013068486A1 (en) | 2011-11-08 | 2013-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of male infertility |
| EP2951287B1 (en) * | 2013-02-04 | 2019-04-03 | ETH Zurich | Designer circuit controlling diet-induced obesity |
| WO2016004286A1 (en) | 2014-07-03 | 2016-01-07 | Momentive Performance Materials Inc. | Ester-functional polysiloxanes and copolymers made therefrom |
| WO2019028096A1 (en) * | 2017-08-02 | 2019-02-07 | The Wistar Institute Of Anatomy And Biology | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
| RU2674987C1 (ru) * | 2018-04-17 | 2018-12-14 | Акционерное общество "Всесоюзный научный центр по безопасности биологически активных веществ" АО "ВНЦ БАВ" | 2-Аминия-7-(диэтиламино)-4-(4-метоксибензо[d][1,3]диоксол-5-ил)-4Н-хромен-3-карбонитрила N-ацетиламиноэтаноат, проявляющий противоопухолевую активность |
| US20220331267A1 (en) * | 2019-09-05 | 2022-10-20 | Rush University Medical Center | Methods and compositions for treatment of demyelinating disorders |
| ES2930093T3 (es) | 2020-11-13 | 2022-12-07 | Serodus Asa | Antagonistas de TNFR1 y agonistas de TNFR2 dobles para uso en enfermedades renales |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8310407D0 (en) * | 1982-05-12 | 1983-05-25 | Ici Plc | 1 3 - dioxan -5- ylalkenoic acids |
| GB8330120D0 (en) * | 1983-11-11 | 1983-12-21 | Ici Plc | Chemical process |
| GB8511890D0 (en) * | 1985-05-10 | 1985-06-19 | Ici Plc | Benzene derivatives |
| EP0201352B1 (en) * | 1985-05-10 | 1992-06-24 | Imperial Chemical Industries Plc | Alkene derivatives |
| GB8626297D0 (en) * | 1986-11-04 | 1986-12-03 | Ici Plc | Pharmaceutical compositions |
| US5248780A (en) * | 1988-02-16 | 1993-09-28 | Imperial Chemical Industries, Plc | Pyridyl substituted alkenoic acid derivatives |
| GB8901201D0 (en) * | 1988-02-16 | 1989-03-15 | Ici Plc | Pyridine derivatives |
| IE81170B1 (en) * | 1988-10-21 | 2000-05-31 | Zeneca Ltd | Pyridine derivatives |
| US5128359A (en) * | 1990-02-16 | 1992-07-07 | Laboratoires Upsa | Benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation |
| ZA911453B (en) * | 1990-03-19 | 1991-11-27 | Squibb & Sons Inc | Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation |
| US5462726A (en) * | 1993-12-17 | 1995-10-31 | Bristol-Myers Squibb Company | Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents |
| US5801195A (en) * | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
| EP0832295A1 (en) | 1995-06-07 | 1998-04-01 | Ligand Pharmaceuticals Incorporated | Method for screening for receptor agonists and antagonists |
| US6028052A (en) | 1995-09-18 | 2000-02-22 | Ligand Pharmaceuticals Incorporated | Treating NIDDM with RXR agonists |
| GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| WO1998043081A1 (en) | 1997-03-26 | 1998-10-01 | Ligand Pharmaceuticals Incorporated | Treatment of gastrointestinal disease with ppar modulators |
| US5981586A (en) * | 1997-05-23 | 1999-11-09 | Pershadsingh; Harrihar A. | Methods for treating proliferative and inflammatory skin diseases |
| US6410245B1 (en) | 1998-04-01 | 2002-06-25 | Affymax, Inc. | Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions |
| US6277884B1 (en) * | 1998-06-01 | 2001-08-21 | Nitromed, Inc. | Treatment of sexual dysfunction with N-hydroxyguanidine compounds |
| US6436997B1 (en) * | 1998-06-01 | 2002-08-20 | Nitromed, Inc. | Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
| AU1179000A (en) * | 1998-11-19 | 2000-06-13 | Shionogi & Co., Ltd. | Preventives and/or remedies for central nervous system diseases containing compounds having TXA2 receptor antagonism and/or TXA2 synthase inhibitory effect |
| US6291496B1 (en) | 1999-12-27 | 2001-09-18 | Andrew J. Dannenberg | Treating cancers associated with overexpression of class I family of receptor tyrosine kinases |
| US6284790B1 (en) * | 2000-06-15 | 2001-09-04 | Sachin Gupte | Methods of potentiating organic nitrates having vasodilating activity and formulations for the same |
| WO2002038157A2 (en) * | 2000-11-09 | 2002-05-16 | The Hospital For Sick Children | Inhibitors of thromboxane formation and action |
| US20030175349A1 (en) * | 2001-01-30 | 2003-09-18 | Council Of Scientific And Industrial Research | Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient |
| US20030104975A1 (en) | 2001-06-14 | 2003-06-05 | Johan Auwerx | Cofactor-based screening method for nuclear receptor modulators and related modulators |
| US6951882B2 (en) * | 2002-12-12 | 2005-10-04 | Janssen Pharmaceutica N.V. | Substituted 4-phenyl-[1,3]-dioxanes |
| AU2003300867A1 (en) * | 2002-12-19 | 2004-07-29 | Synaptic Pharmaceutical Corporation | Uses of the snorf207 receptor |
-
2007
- 2007-01-18 EP EP11166139A patent/EP2363127A1/en not_active Withdrawn
- 2007-01-18 EP EP07804876.6A patent/EP1976509B1/en not_active Not-in-force
- 2007-01-18 ES ES07804876.6T patent/ES2533652T3/es active Active
- 2007-01-18 CA CA002637803A patent/CA2637803A1/en not_active Abandoned
- 2007-01-18 PL PL07804876T patent/PL1976509T3/pl unknown
- 2007-01-18 IN IN502DEN2015 patent/IN2015DN00502A/en unknown
- 2007-01-18 DK DK07804876T patent/DK1976509T3/en active
- 2007-01-18 RU RU2008133416/04A patent/RU2449999C2/ru not_active IP Right Cessation
- 2007-01-18 MX MX2008009241A patent/MX2008009241A/es active IP Right Grant
- 2007-01-18 WO PCT/IB2007/002542 patent/WO2007138485A2/en not_active Ceased
- 2007-01-18 JP JP2008550880A patent/JP2009523781A/ja active Pending
- 2007-01-18 US US12/161,317 patent/US20110178112A1/en not_active Abandoned
- 2007-01-18 AU AU2007266714A patent/AU2007266714B2/en not_active Ceased
-
2008
- 2008-01-18 CN CN200880008956A patent/CN101657100A/zh active Pending
- 2008-01-18 CN CN200880008902.2A patent/CN101657099B/zh active Active
- 2008-01-18 CN CN200880008866A patent/CN101646344A/zh active Pending
-
2012
- 2012-12-28 JP JP2012286467A patent/JP2013060465A/ja not_active Withdrawn
-
2014
- 2014-03-24 US US14/223,621 patent/US20140288110A1/en not_active Abandoned
-
2015
- 2015-07-15 JP JP2015141004A patent/JP2015180703A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009523781A5 (enExample) | ||
| RU2008133416A (ru) | Модуляторы ppar | |
| JP5681108B2 (ja) | ４−アニリノ−３−シアノキノリンとカペシタビンの抗新生物薬の組合せ | |
| US8377971B2 (en) | Non-flushing niacin analogues, and methods of use thereof | |
| JP2015180703A5 (enExample) | ||
| JP2015508749A5 (enExample) | ||
| Schöffski et al. | Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma | |
| JP2010516699A5 (enExample) | ||
| JP2010516701A5 (enExample) | ||
| CA2606719A1 (en) | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same | |
| McLaughlin | Looking to the future: a new decade of pulmonary arterial hypertension therapy | |
| JP2018528206A5 (enExample) | ||
| RU2016127227A (ru) | Производные имидазопиридина в качестве модуляторов активности tnf | |
| JP2009514870A5 (enExample) | ||
| JP2013526497A5 (enExample) | ||
| CN101362718A (zh) | 4-(4-苯甲酰氨基苯氧基)-2-(甲基氨甲酰基)吡啶衍生物及其制备方法和用途 | |
| JP2013545823A5 (enExample) | ||
| JP2010516700A5 (enExample) | ||
| KR20130097775A (ko) | 테오필린과 페북소스타트의 병용 치료 방법 | |
| JP2012526766A5 (enExample) | ||
| CN114401962A (zh) | 作为crbn蛋白调节剂的双并环类化合物 | |
| JP2014527083A5 (enExample) | ||
| JP2014521705A5 (enExample) | ||
| JP2020506159A5 (enExample) | ||
| JP2014510782A5 (enExample) |